IBRX
ImmunityBio, Inc.
There isn't enough reported data to score IBRX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IBRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IBRX's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IBRX PE Valuation
IBRX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IBRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBRX's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.08 | -$0.68 |
| Q2 2026 | -$0.97 | -$0.50 |
| Q1 2026 | -$0.85 | -$0.28 |
| Q4 2025 | -$0.38 | +$0.24 |
| Q3 2025 | -$0.40 | +$0.51 |
| Q2 2025 | -$0.47 | +$0.49 |
| Q1 2025 | -$0.57 | +$0.51 |
| Q4 2024 | -$0.62 | +$0.53 |
IBRX lost $1.08 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IBRX on earnings quality, reporting a profit while its opponent remains loss making.
IBRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.8M | +52% |
| Q2 2026 | $51.2M | +94% |
| Q1 2026 | $44.2M | +168% |
| Q4 2025 | $38.3M | +407% |
| Q3 2025 | $32.1M | +425% |
| Q2 2025 | $26.4M | +2424% |
| Q1 2025 | $16.5M | +41193% |
| Q4 2024 | $7.6M | +5333% |
IBRX has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -160% | +14 points |
| Q2 2026 | -120% | +149 points |
| Q1 2026 | -158% | +232 points |
| Q4 2025 | -169% | +750 points |
| Q3 2025 | -174% | +1141 points |
| Q2 2025 | -270% | +9218 points |
| Q1 2025 | -390% | +237600 points |
| Q4 2024 | -919% | +60512 points |
IBRX's operating margin was −160% last quarter, up 14 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IBRX on profitability, with a higher operating margin.
IBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$78.3M | -$8.6M |
| Q2 2026 | -$70M | +$10.8M |
| Q1 2026 | -$77.1M | +$9.9M |
| Q4 2025 | -$71.3M | +$16M |
| Q3 2025 | -$69.6M | +$31.9M |
| Q2 2025 | -$80.8M | +$20.2M |
| Q1 2025 | -$87M | +$21.2M |
| Q4 2024 | -$87.3M | +$36M |
IBRX has burned cash in almost every quarter: −$297M over the past year, against −$325M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IBRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +10.9M shares |
| 1 year | +12% | +114M shares |
| 3 years | +143% | +623M shares |
| 5 years | +176% | +676M shares |
| Available history | +978% | +963M shares |
IBRX has 1.1B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IBRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IBRX Net Leverage
IBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 29.3 | Neutral |
IBRX's weekly RSI is 39 (neutral) and its Stochastic is 29 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IBRX PE vs Healthcare Sector
IBRX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.70 | 30% below |
| 20 week MA | $8.24 | 26% below |
| 50 week MA | $7.15 | 15% below |
| 100 week MA | $4.93 | 23% above |
| 200 week MA | $4.42 | 37% above |
IBRX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IBRX on trend strength, trading above more of its moving averages.
IBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.74 | $16.0 | +328% |
| 2021 | $16.0 | $7.15 | -55% |
| 2022 | $7.15 | $5.46 | -24% |
| 2023 | $5.46 | $5.02 | -8.1% |
| 2024 | $5.02 | $2.78 | -45% |
| 2025 | $2.78 | $2.14 | -23% |
| 2026 YTD | $2.14 | $6.07 | +184% |
IBRX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.